GLANDPharmaceuticals
Gland Pharma Ltd — PE Ratio & Valuation Analysis
₹1696.10
+0.56%
Current P/E36.01xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E35.1x2.5% above avg
⚠️
13.3% Premium to Industry
GLAND P/E 36.01x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹42.40 | ₹1722 | 40.6x |
| 2024 | ₹46.89 | ₹1779 | 37.9x |
| 2023 | ₹47.43 | ₹1925 | 40.6x |
| 2022 | ₹73.64 | ₹1577 | 21.4x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Gland Pharma Ltd Valuation
Gland Pharma Ltd (GLAND) currently trades at 36.01x earnings. The Pharmaceuticals sector average PE is 31.77x. GLAND commands a premium, reflecting high growth expectations. Historically, GLAND has traded at an average PE of 35.1x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
7.81%
Dividend Yield
1.04%
More on Gland Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.